Gefitinib Plus Interleukin-2 in Advanced Non-Small Cell Lung Cancer Patients Previously Treated with Chemotherapy

por Bersanelli, Melissa, Buti, Sebastiano, Camisa, Roberta, Brighenti, Matteo, Lazzarelli, Silvia, Mazza, Giancarlo, Passalacqua, Rodolfo
Publicado 2014

Prognostic Factors for Post-COVID-19 Syndrome: A Systematic Review and Meta-Analysis

por Maglietta, Giuseppe, Diodati, Francesca, Puntoni, Matteo, Lazzarelli, Silvia, Marcomini, Barbara, Patrizi, Laura, Caminiti, Caterina
Publicado 2022

The Effects of Patient-Reported Outcome Screening on the Survival of People with Cancer: A Systematic Review and Meta-Analysis

por Caminiti, Caterina, Maglietta, Giuseppe, Diodati, Francesca, Puntoni, Matteo, Marcomini, Barbara, Lazzarelli, Silvia, Pinto, Carmine, Perrone, Francesco
Publicado 2022

First-line dose-dense chemotherapy with docetaxel, cisplatin, folinic acid and 5-fluorouracil (DCF) plus panitumumab in patients with locally advanced or metastatic cancer of the s...

por Tomasello, Gianluca, Valeri, Nicola, Ghidini, Michele, Smyth, Elizabeth C., Liguigli, Wanda, Toppo, Laura, Mattioli, Rodolfo, Curti, Alessandra, Hahne, Jens C., Negri, Federica M., Panni, Stefano, Ratti, Margherita, Lazzarelli, Silvia, Gerevini, Fabiana, Colombi, Chiara, Panni, Andrea, Rovatti, Massimo, Treccani, Leonardo, Martinotti, Mario, Passalacqua, Rodolfo
Publicado 2017

Real-life clinical practice results with vinflunine in patients with relapsed platinum-treated metastatic urothelial carcinoma: an Italian multicenter study (MOVIE-GOIRC 01–2014)

por Passalacqua, Rodolfo, Lazzarelli, Silvia, Donini, Maddalena, Montironi, Rodolfo, Tambaro, Rosa, De Giorgi, Ugo, Pignata, Sandro, Palumbo, Raffaella, Ceresoli, Giovanni Luca, Del Conte, Gianluca, Tonini, Giuseppe, Morelli, Franco, Nolè, Franco, Panni, Stefano, Rondini, Ermanno, Guida, Annalisa, Zucali, Paolo Andrea, Doni, Laura, Iezzi, Elisa, Caminiti, Caterina
Publicado 2017

Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy

por Ruzzo, Annamaria, Graziano, Francesco, Galli, Francesca, Galli, Fabio, Rulli, Eliana, Lonardi, Sara, Ronzoni, Monica, Massidda, Bruno, Zagonel, Vittorina, Pella, Nicoletta, Mucciarini, Claudia, Labianca, Roberto, Ionta, Maria Teresa, Bagaloni, Irene, Veltri, Enzo, Sozzi, Pietro, Barni, Sandro, Ricci, Vincenzo, Foltran, Luisa, Nicolini, Mario, Biondi, Edoardo, Bramati, Annalisa, Turci, Daniele, Lazzarelli, Silvia, Verusio, Claudio, Bergamo, Francesca, Sobrero, Alberto, Frontini, Luciano, Magnani, Mauro
Publicado 2019

Author Correction: Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy

por Ruzzo, Annamaria, Graziano, Francesco, Galli, Francesca, Galli, Fabio, Rulli, Eliana, Lonardi, Sara, Ronzoni, Monica, Massidda, Bruno, Zagonel, Vittorina, Pella, Nicoletta, Mucciarini, Claudia, Labianca, Roberto, Ionta, Maria Teresa, Bagaloni, Irene, Veltri, Enzo, Sozzi, Pietro, Barni, Sandro, Ricci, Vincenzo, Foltran, Luisa, Nicolini, Mario, Biondi, Edoardo, Bramati, Annalisa, Turci, Daniele, Lazzarelli, Silvia, Verusio, Claudio, Bergamo, Francesca, Sobrero, Alberto, Frontini, Luciano, Magnani, Mauro
Publicado 2020

Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patients

por Ruzzo, Annamaria, Graziano, Francesco, Galli, Fabio, Giacomini, Elisa, Floriani, Irene, Galli, Francesca, Rulli, Eliana, Lonardi, Sara, Ronzoni, Monica, Massidda, Bruno, Zagonel, Vittorina, Pella, Nicoletta, Mucciarini, Claudia, Labianca, Roberto, Ionta, Maria Teresa, Veltri, Enzo, Sozzi, Pietro, Barni, Sandro, Ricci, Vincenzo, Foltran, Luisa, Nicolini, Mario, Biondi, Edoardo, Bramati, Annalisa, Turci, Daniele, Lazzarelli, Silvia, Verusio, Claudio, Bergamo, Francesca, Sobrero, Alberto, Frontini, Luciano, Magnani, Mauro
Publicado 2014